Insulet Corporation (PODD) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
Insulet's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Insulet's ROI in the third quarter of 2026? Insulet Corporation achieved a return on average invested assets (ROI) of 14.18 % in its third quarter of 2026, this is above PODD's average return on investment of -6.58%. Insulet Corporations investments during the 12 months ending in the third quarter of 2026 are valued at $3 billion
ROI has improved compared to 13.66% in the second quarter of 2026, due to net income growth.
Within the Healthcare sector 40 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 622, from total ROI ranking in the second quarter of 2026 at 979.
ACTON, Mass. - In a strategic move to strengthen its financial leadership, the global leader in tubeless insulin pump technology, Insulet Corporation (NASDAQ: PODD), has announced the appointment of Ana Maria Chadwick as Executive Vice President, Chief Financial Officer (CFO), and Treasurer. Chadwick will assume her new role effective April 22, 2024, signaling an exciting new chapter for the company. The selection of Chadwick as CFO comes after an extensive search process conducted by Insulet Corporation, which sought an individual who could contribute to maintaining and expanding the company s success. With her extensive financial expertise and strategic insights, Chadwick is poised to play a pivotal role in driving the company s growth trajectory.
Insulet Announces Changes to Board of Directors with Retirements and New Appointments ACTON, Mass. - Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod brand of products, is proud to announce significant changes to its Board of Directors. These changes, effective January 18, reflect the company s commitment to expert guidance and strategic leadership as it continues to revolutionize the healthcare industry. Joining the esteemed board are Flavia Pease, Corporate Executive Vice President and Chief Financial Officer at Charles River Laboratories, and Timothy Stonesifer, Chief Financial Officer at Alcon Inc. Both industry leaders bring a wealth of experience and expertise to Insulet. Their appointments demonstrate the company s dedication to attracting top talent and strengthening its financial management capability.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
